The purpose of this study is to evaluate the acceptability and safety of switching to Suboxone® (buprenorphine plus naloxone) and the effect of the switch on medication dispensing. Subjects, for whom a therapy with Suboxone® is indicated and planned prior to study enrollment and who are willing to participate, will initiate therapy on Day 1 of the study. The dosage will be adjusted between Day 2 to 7 depending on patient's needs and determined by the treating physicians in accordance with the SmPC of Suboxone®. Data will be collected at baseline, day 1 til 7, the end of weeks 2 and 4 and monthly up to the end of Month 12.

Nonprobability sampling was done by invitation to volunteer.

Inclusion Criteria:

• All patients on substitution therapy, that are willing to switch to Suboxone, can be included.
• Therapeutic indications and contraindications for Suboxone® must be taken into consideration when selecting patients.

Exclusion Criteria:

• According to product information
• In accordance with the product information pregnant women will be excluded.

All patients on substitution therapy for opioid dependence willing to switch to Suboxone

Adverse events were collected for total observational time of each patient: from start of treatment until end of observation or date of early discontinuation, respectively - maximum period 1 year

For description of safety data all patients enrolled and exposed to Suboxone® for at least one day(N=339) were included in the safety analysis